HDAX Therapeutics’ Post

Saw something interesting on BioSpace today, link below. https://lnkd.in/eYMThisM The SparkNotes version is VC firm Scion Life Sciences launched on Wednesday with $310M to fund companies working on curative therapies. The firm is led by three biotech veterans and looking to build a platform for companies developing treatments of life-threatening diseases to grow on. While already establishing four companies, they are looking to continue funding companies with the ultimate goal of changing lives. This isn't something we see everyday, but something we should see more of. Excited to see what comes out of Scion Life Sciences. Leave your thoughts and comments below, and let me know if you would like to chat further on this. #biotech #innovation #vcfunding

📣 Application call for our early-stage startups in drug development and delivery! 🗓️ Hand in your pitch deck until June 16, 2024 All details in the post below. #startups #entrepreneurship #lifesciences

🎓 Biotech Investing Masterclass with Cytonics' CEO Joey Bose 📅 Mark Your Calendars! Date: January 12, 2024 Time: 4 PM Eastern Time (US and Canada) 🌐 Register here: https://lnkd.in/ebEsmZTn 📣 Attention all investors and biotech enthusiasts! We're thrilled to invite you to an exclusive webinar that promises to demystify the world of biotechnology investing. 💡 Join us for "Biotech Investing Unveiled," where our President & CEO, Joey Bose, will offer a rare peek behind the curtain of the biotech industry. This is your chance to learn directly from a seasoned expert at the helm of a leading biotech company. Joey's unique blend of expertise in biomedical engineering and investment banking makes him the perfect guide to navigate the complex yet fascinating world of biotech. 🔬 What's On the Agenda? ✅Cytonics' Evolution: Trace our journey from a 2006 startup to a disruptor in the #osteoarthritis research arena. ✅ Drug Development Breakthroughs: Dive deep into the challenges and triumphs of the drug development process, especially the path to FDA approval. ✅ Empowering Future Medicine: Understand how #biotech investments fuel medical advancements and how we responsibly utilize investor funds in our mission. ✅ Interactive Q&A Session (30 min): Your chance to ask Joey anything about biotech, scientific research, investment strategies, and the broader economic landscape affecting your portfolio. 👨💼 Meet Joey Bose, President & CEO With a rich background in both science and finance, Joey is uniquely positioned to offer insights into the intersection of biotech and investment. Don't miss this opportunity to learn from his wealth of knowledge. 🤝 A Community of Visionaries We're beyond grateful for the incredible momentum of our equity crowdfunding campaign. A heartfelt thanks to the 450+ investors who've joined us, contributing over $1.1 million in just 3 weeks. Your support is a testament to our shared belief in transforming regenerative medicine. Become an investor: invest.cytonics.com 💥 Don't miss this chance to gain valuable insights and be part of our groundbreaking journey. Register now and be part of the conversation shaping the future of medicine! #biotechnology #investing #regenerativemedicine

🎓 Biotech Investing Masterclass with Cytonics' CEO Joey Bose 📅 Mark Your Calendars! Date: January 12, 2024 Time: 4 PM Eastern Time (US and Canada) 🌐 Register here: https://lnkd.in/eyRedZsN 📣 Attention all investors and biotech enthusiasts! We're thrilled to invite you to an exclusive webinar that promises to demystify the world of biotechnology investing. 💡 Join us for "Biotech Investing Unveiled," where our President & CEO, Joey Bose, will offer a rare peek behind the curtain of the biotech industry. This is your chance to learn directly from a seasoned expert at the helm of a leading biotech company. Joey's unique blend of expertise in biomedical engineering and investment banking makes him the perfect guide to navigate the complex yet fascinating world of biotech. 🔬 What's On the Agenda? ✅Cytonics' Evolution: Trace our journey from a 2006 startup to a disruptor in the #osteoarthritis research arena. ✅ Drug Development Breakthroughs: Dive deep into the challenges and triumphs of the drug development process, especially the path to FDA approval. ✅ Empowering Future Medicine: Understand how #biotech investments fuel medical advancements and how we responsibly utilize investor funds in our mission. ✅ Interactive Q&A Session (30 min): Your chance to ask Joey anything about biotech, scientific research, investment strategies, and the broader economic landscape affecting your portfolio. 👨💼 Meet Joey Bose, President & CEO With a rich background in both science and finance, Joey is uniquely positioned to offer insights into the intersection of biotech and investment. Don't miss this opportunity to learn from his wealth of knowledge. 🤝 A Community of Visionaries We're beyond grateful for the incredible momentum of our equity crowdfunding campaign. A heartfelt thanks to the 450+ investors who've joined us, contributing over $1.1 million in just 3 weeks. Your support is a testament to our shared belief in transforming regenerative medicine. Become an investor: invest.cytonics.com 💥 Don't miss this chance to gain valuable insights and be part of our groundbreaking journey. Register now and be part of the conversation shaping the future of medicine! #biotechnology #investing #regenerativemedicine

Foresite Capital Launches $900M Biotech Fund Foresite Capital, under the leadership of Jim Tananbaum, M.D., has gathered a staggering $900 million for their latest fund, signaling a bullish stance in what is considered one of the top investment environments for biotech. Since its inception in 2011, Foresite has played a significant role in propelling innovation at the nexus of technology and biology. Their sixth fund is set to escalate advancements in precision therapeutics, life science technologies, and healthcare systems. Portfolio companies such as Alumis, Latigo Biotherapeutics, and Xaira Therapeutics have experienced substantial funding rounds, ranging from $135M to $1B, despite the overall contraction in investment flows. With a robust track record of 47 IPOs, noteworthy acquisitions, and 58 FDA approvals for novel medicines, Foresite's strategies are proven to foster monumental health sector breakthroughs. Jim Tananbaum envisions the fusion of biology, genomics, and AI initiating a transformative chapter for patient care and investor revenue. #BiotechInvestment #PrecisionTherapeutics #HealthcareInnovation

Enveda Biosciences Secures $55M to Advance AI-Driven Drug Discovery - Major Funding Round: Enveda Biosciences, a biotech firm specializing in AI-driven drug discovery, raised $55M in a Series B2 round, bringing total funding to $230M. - Strategic Investors: New investors include Premji Invest, Lingotto Investment Fund, Microsoft, and The Nature Conservancy, with continued support from existing backers. - Advancing Drug Development: Funds will enhance Enveda’s AI platform and support Phase I clinical trials for three lead programs, including a novel treatment for atopic dermatitis. Subscribe to our daily newsletter here for more AI news https://lnkd.in/d_cKz6EH #AI #Healthcare #Innovation #Technology #Future #Startups #Entrepreneurship #VentureCapital #ArtificialIntelligence #DigitalMarketing

🚀Introducing another one of #AltiusBioventures Founding Partners, Lee Buckler! I'm Lee Buckler, co-founding partner of Altius Bioventures. I've had the pleasure of working in the cell therapy industry now for 20+ year and am incredibly blessed to have dedicated most of my career to an industry I fall in love with a little more each day and to have benefitted from growing up alongside its pioneers. 🧬The entire success of the industry to-date is built on using tools which were not designed for the purpose or, if they were, we now have whole other level of purpose which we demand of them. We now have an opportunity to redesign all of our tools with the functional, technical, and commercial specifications we understand so much better. We now also have an imperative to ensure our tools are smart or can be embedded into smart platforms - with digital inputs, outputs, and analytical capabilities. This kind of built-for-the-purpose and digitization strategy will allow us to incorporate and leverage next-generation technologies involving automation, nano/micro-fluidics, analytics, AI/ML, etc with the goal of ensuring our tools are driving us to a future where manufacturing is closed and the therapies they produce are 'accessible' by every definition of that word. 📈 What makes Altius special is not the business model but its laser-like focus, its people, and its depth of expertise. No other bioventure is singly focused on cell therapy manufacturing and analytical tools, technologies, and services driven by a managing and supporting cast with the depth of expertise and breadth of network as Altius. Having said that we will have only a small fund so it will be critical we co-invest, engage with follow-on investors and work in concert with investors of all stripes and strategic partners to ensure the success of the companies we help mature with our early-stage funding and support. 🏆 I'll be heading up what we call the "sourcing team" which is about scouting opportunities wherever we find them, sifting them through our Altius criterion, selecting those to put through due diligence, and finding the gems we select to recommend with a report of our assessment to the Investment Committee for their evaluation. I'm sure on the back-end I'll also have a role to play in finding the right strategic partners for these companies or assets within the big company ecosystem if/when that's appropriate.

🚀 Launching the Nucleate Denmark Activator Program 2024 🚀 📢 We are very excited to announce that the first edition of the Activator has officially begun! This 5-month company creation program is designed to identify and support promising bio-entrepreneurs to turn impactful research into thriving life science companies in Denmark. Over the last months, we carefully selected 6 teams to embark on this journey, each chosen for the potential of their transformative ideas. Every team comprises inventors (academic trainees with visionary ideas) and contributors (students who bring expertise in areas such as clinical or business). We are delighted to be running the program with 16 inventors and 13 contributors, which creates a very rich environment for cross-disciplinary collaboration and knowledge exchange! The first Nucleate Denmark Activator Cohort consists of 4 Bio💊 teams, specialised in therapeutics and diagnosis, and 2 Eco♻️, focused on sustainability. More details on all the teams will be revealed in the coming weeks, but for now take good note of their names: SkyDye, BioHalo, Idun Biologics ApS, Immunite, KPL and 1st Biome. 🎤 Last week, we organised a reception event to inaugurate the Activator where we introduce the teams to some exciting opportunities for the coming months and give practical information about the program. Additionally, each team had the opportunity to pitch their technology and introduce their group to all the Activator participants. We also had the privilege to have Jens Viktor Nørgaard from HØIBERG - European Patent Attorneys and Philip Hesselbjerg from Horten Advokatpartnerselskab as speakers, representing two of the companies that will be supporting the program by providing expert knowledge and guidance to the teams in several workshops. Additionally, we counted on the presence of our colleague from Nucleate UK, Maja Wojtynska, on behalf of BlueYard Capital, who is willing to invest $2M in uncapped SAFE notes among European teams. 📆 The Activator will run until the beginning of June, culminating in an open Demo Day where all teams will pitch their ideas. Stay tuned over the coming months as we continue to share more insights about the program! #Innovation #Biotechnology #Entrepreneurship #TheActivator

🚀 Private Biotech Funding Surges! 🚀 Q1 of 2024 saw a significant uptick in private biotech funding, with U.S. and European drugmakers raising a whopping $6.8 billion in venture capital. This nearly $1 billion increase from the most active quarter of 2023 highlights the sector's growing momentum and investor confidence. Twenty-six biotechs closed fundraising rounds exceeding $100 million, showcasing both the strategic investment in cancer and neurological drug development and the return of large syndicates and new investors. Notably active firms include OrbiMed, Arch Venture Partners, GV, and RA Capital Management. This surge in funding underscores robust biopharma activity. Will this trend persist, or is there a risk of overheating? Only time will tell. #BioTech #VentureCapital #HealthTech

📰 The Kapnative Newsletter Edition 7 🌐 This Week's Edition Highlights: 1️⃣ Archimed's Phenomenal Success: French private equity firm Archimed achieved an extraordinary 300x MOIC with the acquisition of Polyplus, a healthcare company. Shifting focus to Cell & Gene Therapy led to substantial EBITDA growth. 2️⃣ Private Equity Trends: Adaptations Amid Challenges; Private equity firms, including Thoma Bravo and Permira, prioritize portfolio sales in 2024 amidst challenging exits. Notable sales include potential deals by Hellman & Friedman and PAI Partners. The sector adapts to realistic pricing, increased bank lending, and aims to demonstrate the profitability of take-private deals. 3️⃣ Mirae Asset's U.S. Biotech Venture Fund: Mirae Asset Financial Group launches a $50 million U.S.-based biotech venture-capital fund. Headed by Dr. Naveen Krishnan, the fund targets U.S. life sciences startups, reflecting Mirae's active participation in top U.S. life sciences deals. 🚀 Stay Tuned for More Insights!  Stay ahead in the world of alternative investments. Our mission is to keep you well-informed and prepared for the exciting opportunities in the ever-evolving financial landscape.